

# Cardiometabolic Research Fellowship

## TERMS & CONDITIONS

The Cardiometabolic Research Fellowship (**Fellowship**) is an annual initiative designed to support early- to mid-career clinicians undertaking translational and implementation research in cardiometabolic health across Australia and New Zealand. The Fellowship provides funding, recognition, and structured oversight to support high-impact research projects.

### 1. Definitions

For purposes of these Terms and Conditions:

**Applicant** refers to any individual who initiates and/or submits an application for the Fellowship via the official online platform.

**Cardiometabolic Summit** refers to Novo Nordisk's annual Cardiometabolic Summit, a multidisciplinary national forum which brings together specialists to advance understanding and best practice in cardiometabolic disease management.

**Cardiometabolic Summit Events** refers to the official finalist activities and the award announcement events.

**Fellowship** refers to the Cardiometabolic Research Fellowship, including all associated awards, recognition, and events.

**Fellowship Funds** refers to the monetary award of AUD\$100,000 which will be paid to the Recipient's nominated Institution/Organisation and disbursed by that Institution/Organisation to support the Recipient's research project under the Fellowship.

**Judging Panel** refers to the group of individuals appointed to assess applications and determine the Recipient of the Fellowship.

**Personal Data** refers to any information collected during the application process that can identify an individual, including name, contact details, career history, and personal statements.

**Promotional Materials** refers to content such as photographs, biographies, and media interviews used to promote the Fellowship and its Recipients.

**Recipient** refers to the Applicant selected by the Judging Panel to receive the Fellowship.

**Submission Guidelines** refers to the supplementary document provided to Applicants outlining the detailed instructions and expectations for preparing and submitting a competitive application.

## **2. Prize Structure & Disbursement**

One Recipient will be selected each year. The Fellowship includes the Fellowship Funds which will be provided to support the Recipient's approved research project, subject to applicable governance and reporting requirements. The Fellowship Funds will be provided to the Recipient's nominated Institution/Organization for disbursement and administration.

The Recipient will be formally announced at the Cardiometabolic Summit and is expected to present their research outcomes or interim results at the Cardiometabolic Summit in the year following their receipt of the Fellowship.

All monetary awards paid under the Fellowship are provided as united financial support unless otherwise specified.

Subject to confirmation of bank details and compliance with requirements, the Fellowship Funds will be transferred to Recipient's nominated Institution/Organisation within 60 days after written acceptance by the Recipient and their nominated Institution/Organisation of the Fellowship terms as set by Novo Nordisk.

The Recipient must use (and the Institution/Organisation may only disburse) the Fellowship Funds solely for the purposes outlined in the research proposal for which the Fellowship was awarded. The Fellowship Funds must be managed in accordance with institutional policies and any additional conditions communicated by the Fellowship administrators.

Misuse of the Fellowship Funds may result in withdrawal of the Fellowship and/or repayment obligations.

The Recipient agrees to:

- Undertake the research project for which the Fellowship was awarded within the agreed timeframes.
- Participate in oversight, mentoring, and reporting activities as required by the Institution/Organisation and Judging Panel.
- Comply with all ethical, regulatory, and governance requirements.
- Acknowledge the Fellowship in publications and presentations related to the Fellowship funded research.

## **3. Eligibility Criteria**

As at the application closing date, Applicants must:

- Be an Australian or New Zealand citizen or permanent resident.
- Be based in Australia or New Zealand.
- Be at an early-career stage, typically defined as within five (5) years of conferral of highest postgraduate degree (MSC, MPH, PhD or equivalent).
- Be professionally engaged in medical practice within Cardiometabolic disciplines.
- Have no substantiated findings of professional, academic, or ethical misconduct.
- Be supported by their nominated Institution/Organisation, which support is confirmed in an attached letter that also confirms the applicant's good standing.

- Be available and willing to attend the Cardiometabolic Summit in May of the award year and to present their research findings (interim or final) at the Cardiometabolic Summit in the following year.

#### **4. Entry Requirements**

Entries must be submitted via the official online application platform by the published deadline. Late or incomplete submissions will not be accepted.

Applicants are responsible for ensuring that all information provided is accurate, complete, and truthful. Any misrepresentation may result in disqualification.

Applicants must include all required materials as specified in the application form. Finalists may be asked to provide additional materials for promotional purposes, such as a photograph or biography.

By submitting an application for the Fellowship, Applicants:

- consent to the use of their name, likeness, and biographical information by Novo Nordisk for promotional and media purposes related to the Fellowship; and
- accept these Terms and Conditions.

#### **5. Selection Process**

The Recipient will be chosen by a Judging Panel composed of esteemed figures from academia, industry, and healthcare. The decision of the Judging Panel is final, and no correspondence will be entered into.

All eligible applications will undergo a competitive, merit-based assessment process. Applications will be reviewed and scored against published evaluation criteria, including scientific merit, translational impact, strategic alignment, innovation, feasibility, applicant capability, and appropriate use of funding.

Shortlisted Applicants may be subject to further review and panel deliberation. In the event of closely ranked applications, a mediation process may be undertaken to reach a final decision.

Applicants are strongly encouraged to refer to the **Submission Guidelines** document when preparing their application. This document provides detailed guidance on how to address the selection criteria and present a competitive submission.

#### **6. Announcement and Recognition**

The Recipient will be notified in writing by use of their nominated contact email prior to the Cardiometabolic Summit.

The Recipient will be announced at the Cardiometabolic Summit in the year of their application. For the Fellowship offered in 2026, this will be at an event held at the Cardiometabolic Summit in Melbourne on 23 May 2026.

#### **7. Cardiometabolic Summit Event Attendance**

The Recipient will be required to attend the following events in Melbourne:

- Cardiometabolic Summit 23 and 24 May 2026; and
- The **award announcement event** in the evening 23<sup>rd</sup> May 2026

In accordance with its policies and compliance requirements, Novo Nordisk will pay the reasonable costs for domestic travel and accommodation for the Recipient, including:

- Return economy airfares or equivalent transportation;
- One night's accommodation (two nights if required due to travel times/distances in accordance with Novo Nordisk's policies and compliance requirements); and
- Ground transfers to/from the airport and event venues.

Travel insurance is the responsibility of the Recipient.

## **8. Publicity and Media**

The Recipient agrees to:

- Participate in media opportunities, including interviews and photographs.
- Allow Novo Nordisk to use their name, likeness, and biographical information in promotional materials related to the Fellowship.

The Recipient will be consulted prior to the release of any major media statements or public announcements.

## **9. Confidentiality and Intellectual Property**

All applications and supporting materials will be treated as confidential.

All intellectual property rights in or to any material included in the application and/or developed, produced or created during the Fellowship program remains the sole property of the Applicant. Submission of an application does not imply the transfer of any intellectual property rights to Novo Nordisk.

## **10. Taxation and Financial Disclosure**

The Fellowship Funds may be considered assessable income under Australian Taxation Office (ATO) guidelines. The Recipient is advised to seek independent financial and tax advice. Novo Nordisk bears no responsibility for any tax liabilities incurred.

## **11. Compliance with Australian Law**

This Fellowship operates in accordance with:

- The Charitable and Not-for-Profit Guidelines (where applicable);
- Relevant State and Territory trade promotion and prize-giving regulations; and
- Privacy Act 1988 (Cth) – All personal information collected will be handled in accordance with the privacy policy of Novo Nordisk available at: [Privacy Policy](#).

The Fellowship is not considered a game of chance or trade promotion lottery, and as such, no permit is required under current Australian legislation. However, should future promotional mechanisms change, appropriate legal advice will be sought.

## **12. Withdrawal or Forfeiture**

Novo Nordisk reserves the right to:

- Withhold distribution of Fellowship Funds in cases of misconduct, misrepresentation, or eligibility breaches.
- Revoke the Fellowship, including the Fellowship Funds, if new information emerges that materially affects the Recipient's eligibility or the integrity of the Fellowship.

## **13. Reporting and Impact Tracking**

In support of long-term Fellowship program evaluation, the winner of the Fellowship is encouraged to submit a written impact statement within 12 months after completing the 12 month Fellowship period. This statement could include:

- Professional achievements or milestones reached as a result of the Fellowship;
- Broader impacts on the Recipient's research, collaboration, or community engagement.

### **15. Diversity and Equity Considerations**

Novo Nordisk is committed to fostering an inclusive environment and encourages applications from individuals of all backgrounds, including from under-represented communities. All applications will be assessed equitably and without bias.

### **16. Feedback and Dispute Resolution**

To ensure the integrity and fairness of the judging process, feedback will not be provided to Applicants at any stage of the selection process.

All decisions made by the judging panel are final. Any disputes or complaints will be managed in accordance with Novo Nordisk's formal dispute resolution policy, and no correspondence will be entered into regarding the outcome of applications.

### **17. Other Terms and Conditions**

#### **17.1 Costs and Expenses**

There is no fee to submit an application for the Fellowship.

Novo Nordisk is not liable for any loss, damage, or expenses incurred by Applicants in connection with the preparation, submission, or follow-up of their application.

#### **17.2 Data Privacy and Consent**

All personal data collected as part of the application process will be handled in accordance with the Australian Privacy Principles (APPs) and Novo Nordisk's [Privacy Policy](#).

This includes, but is not limited to, information such as name, contact details, career history, and personal statements.

- Data will be accessed only by the judging panel and authorised administrative staff.
- Personal data will be retained only for as long as necessary to administer the Fellowship.
- Applicants may request access to, or deletion of, their personal data at any time by contacting: [privacyofficeroceania@novonordisk.com](mailto:privacyofficeroceania@novonordisk.com).

By submitting an application, Applicants consent to the collection, use, and storage of their personal data for the purposes of administering the Fellowship.

#### **17.3 Legal Disclaimers and Liability**

Novo Nordisk reserves the right to:

- Amend the terms of the Fellowship, including eligibility criteria, judging criteria, timelines, or award structure, at its sole discretion.
- Cancel, suspend, or modify the Fellowship at any time without prior notice, where necessary due to unforeseen circumstances or events beyond its control.

Participation in the Fellowship does not guarantee selection or award.

Novo Nordisk accepts no responsibility for any technical issues, delays, or failures in the submission process, or for any consequences arising from participation in the Fellowship.